Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization.
Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization.
复制标题
血清LAG-3预测跨性质化学栓塞患者的肝细胞癌患者的结果和治疗反应。
DOI：
10.3389/fimmu.2021.754961
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Xia J
中科院分区：
文献类型：
--
作者：
Guo M;Qi F;Rao Q;Sun J;Du X;Qi Z;Yang B;Xia J
经动脉化疗栓塞术（TACE）是目前世界范围内治疗肝细胞癌（HCC）最常用的方法。本研究旨在探讨LAG-3和PD-L1作为血清生物标志物在接受TACE治疗的HCC患者中的潜在预测和预后作用。共有100名接受TACE的HCC患者以及30名健康对照入组研究。在基线和TACE后3天使用酶联免疫吸附试验（ELISA）测定血清LAG-3和PD-L1水平。我们发现，与健康对照组相比，HCC患者的血清LAG-3和PD-L1水平显著升高。有趣的是，TACE前和TACE后LAG-3水平较低但PD-L1水平不高的患者在TACE治疗后实现客观缓解（OR）的概率较高。此外，TACE前LAG-3水平高与疾病结局差相关，血清LAG-3和PD-L1水平均高的患者的总生存期（OS）短于PD-L1或LAG-3高或PD-L1和LAG-3均低的患者。TACE前血清LAG-3水平高与肝硬化类型、晚期BCLC分期、TACE前丙氨酸氨基转移酶（ALT）水平和TACE前天冬氨酸氨基转移酶（AST）水平呈正相关。此外，在50例接受TACE的患者中，TACE后3天血清LAG-3水平显着降低。TACE前后血清LAG-3水平均可以作为TACE疗效的有力预测指标，TACE前血清LAG-3水平高是HCC预后不良的指标。
Transarterial chemoembolization (TACE) stands for the most commonly utilized therapy for hepatocellular carcinoma (HCC) worldwide. This study was to explore the potential predictive and prognostic roles of LAG-3 and PD-L1 as serum biomarkers in HCC patients underwent TACE treatment. A total of 100 HCC patients receiving TACE as well as 30 healthy controls were enrolled in the study. Serum LAG-3 and PD-L1 levels were determined at baseline and 3 day after TACE using enzyme-linked immunosorbent assay (ELISA). We found serum levels of LAG-3 and PD-L1 were significantly elevated in HCC patients compared with healthy controls. Interestingly, patients with low pre-TACE and post-TACE levels of LAG-3 but not PD-L1 had a high probability of achieving an objective response (OR) after TACE treatment. Additionally, high pre-TACE LAG-3 level was correlated with poor disease outcome, and the patients with both high serum LAG-3 and PD-L1 level had the shorter overall survival (OS) than patients who are either PD-L1 or LAG-3 high or both PD-L1 and LAG-3 low. High pre-TACE serum LAG-3 level was positively associated with more cirrhosis pattern, advanced BCLC stage, pre-TACE alanine aminotransferase (ALT) level, and pre-TACE aspartate aminotransferase (AST) level. Furthermore, in 50 patients who underwent TACE, the serum LAG-3 level was significantly decreased at 3 day after TACE. Both pre-TACE and post-TACE serum LAG-3 levels could serve as powerful predictors for tumor response of TACE, and high pre-TACE serum LAG-3 level was an indicator for poor prognosis in HCC.